Haloperidol-loaded polysorbate-coated polymeric nanocapsules decrease its adverse motor side effects and oxidative stress markers in rats

Neurochemistry International

Volumn 61, Issue 5, 2012, Pages 623-631

  Benvegnú, Dalila Moter ^a   Barcelos, Raquel Cristine Silva ^a   Boufleur, Nardeli ^a   Pase, Camila Simonetti ^a   Reckziegel, Patrícia ^a   Flores, Fernanda Cramer ^a   Ourique, Aline Ferreira ^b   Nora, Magali Dalla ^a   Silva, Cristiane De Bona Da ^a   Beck, Ruy Carlos Ruver ^b   Bürger, Marilise Escobar ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Extrapyramidal effects; Haloperidol; Orofacial dyskinesia; Oxidative stress; Polymeric nanocapsule

Indexed keywords

CELL MARKER; FISH OIL; GLUTATHIONE; HALOPERIDOL; NANOCAPSULE; POLYCAPROLACTONE; POLYSORBATE; POLYSORBATE 80; SORBITAN STEARATE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALEPSY; CLINICAL EVALUATION; CONTROLLED STUDY; DYSKINESIA; ENCAPSULATION; ENZYME BLOOD LEVEL; HUMAN; LIPID PEROXIDATION; LOCOMOTION; MALE; MOTOR ACTIVITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; RAT; ZETA POTENTIAL;

ANIMALS; DRUG CARRIERS; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; MALE; MOTOR ACTIVITY; NANOCAPSULES; OXIDATIVE STRESS; POLYMERS; POLYSORBATES; RATS; RATS, WISTAR;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

EID: 84865610860     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2012.06.015     Document Type: Article

References (51)

1. H. Aebi Catalase in vitro Methods Enzymol. 5 1984 121 126
2. O.A. Andreassen, and H.A. Jorgensen Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats-Implications for tardive dyskinesia? Prog. Neurobiol. 61 2000 525 541
3. R.C.S. Barcelos, D.M. Benvegnú, N. Boufleur, P. Reckziegel, L. Muller, C. Pase, T. Emanuelli, and M.E. Burger Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter Neurotox. Res. 17 2010 228 237
4. R.C.S. Barcelos, D.M. Benvegnú, N. Boufleur, C.S. Pase, A.M. Teixeira, P. Reckziegel, T. Emanuelli, and J.B.T. Rocha Burger ME. Short term dietary fish oil supplementation improves motor deficiencies related to reserpine-induced parkinsonism in rats Lipids 46 2011 143 149
5. N.G. Bazan Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection Clin. Nutr. Metab. Care 10 2007 136 141
6. R.C.R. Beck, A.R. Pohlmann, E.V. Benvenutti, T.C. Dalla Costa, and S.S. Guterres Nanostructure-coated diclofenac-loaded microparticles: preparation, morphological characterization, in vitro release and in vivo gastrointestinal tolerance J. Braz. Chem. Soc. 16 2005 1233 1240
7. R.C.R. Beck, S.E. Haas, S.S. Guterres, M.I. Ré, E.V. Benvenutti, and A.R. Pohlmann Nanoparticle-coated organic-inorganic microparticles: experimental design and gastrointestinal tolerance evaluation Quím. Nova 29 2006 990 996
8. D.M. Benvegnú, R.C.S. Barcelos, N. Boufleur, P. Reckziegel, C.S. Pase, A.F. Ourique, R.C.R. Beck, and M.E. Burger Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats Eur. J. Pharm. Biopharm. 77 2011 332 336
9. A. Bernardi, E. Braganhol, E. Jaeger, F. Figueiro, M.I. Edelweiss, A.R. Pohlmann, S.S. Guterres, and A.M.O. Battastini Indomethacin-loaded nanocapsules treatment reduces in vivo glioblastoma growth in a rat glioma model Cancer Lett. 281 2009 53 63
10. A. Bernardi, R.L. Frozza, A.P. Horn, M.M. Campos, J.B. Calixto, C. Salbego, A.R. Pohlmann, S.S. Guterres, and A.M.O. Battastini Protective effects of indomethacin-loaded nanocapsules against oxygen-glucose deprivation in organotypic hippocampal slice cultures: involvement of neuroinflammation Neurochem. Int. 57 2010 629 636
11. A.F. Boyne, and G.L. Ellman A methodology for analysis of tissue sulfhydryl components Anal. Biochem. 46 1972 639 653
12. M.E. Burger, J.B.T. Rocha, R. Fachinetto, and L. Callegari Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain Pharmacol. Biochem. Behav. 81 2005 608 615
13. M.E. Burger, R. Fachinetto, A. Alves, L. Calegari, and J.B.T. Rocha Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats Brain Res. 1031 2005 202 210
14. M.E. Burger, J.B.T. Rocha, R. Fachinetto, G. Zeni, J. Perottoni, C. Wagner, and R.P. Pereira Effects of diphenyl-diselenide on orofacial dyskinesia model in rats Brain Res. Bull. 70 2006 165 170
15. G. Colpo, F. Trevizol, A.M. Teixeira, R.P. Pereira, J.B.T. Rocha, and M.E. Burger Ilex paraguariensis has antioxidant potential and attenuates haloperidol-induced orofacial dyskinesia and memory dysfunction in rats Neurotox. Res. 12 2007 1 10
16. I. Creese, D.R. Burt, and S.H. Snyder Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs J. Neuropsychiatry Clin. Neurosci. 8 1996 223 226
17. R. Fachinetto, J.G. Villarinho, C. Wagner, R.P. Pereira, M.E. Burger, J.B.T. Rocha, J. Ferreira, and J.B. Calixto Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 1478 1486
18. H. Fessi, F. Puisieux, J.P. Devissaguet, N. Ammoury, and S. Benita Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 55 1989 r1 r4
19. M.C. Fontana, J.F.P. Rezer, K. Coradini, D.B.R. Leal, and R.C.R. Beck Improved efficacy in the treatment of contact dermatitis in rats by a dermatological nanomedicine containing clobetasol propionate Eur. J. Pharm. Biopharm. 79 2011 241 249
20. A. Friese, E. Seiller, G. Quack, B. Lorenz, and J. Kreuter Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system Eur. J. Pharm. Biopharm. 49 2000 103 109
21. R.L. Frozza, A. Bernardi, K. Paese, J.B. Hoppe, T. Silva, A.M. Battastini, A.R. Pohlmann, S.S. Guterres, and C. Salbego Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats J. Biomed. Nanotechnol. 6 2010 694 703
22. 1 encapsulated into lipid nanoparticles improves its anti-inflammatory effect with low side-effect Int. J. Pharm. 387 2010 263 271
23. E. Garcia-Garcia, K. Andrieux, S. Gil, and P. Couvreur Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298 2005 274 292
24. B. Halliwel, and J.M.C. Gutteridge Free Radicals in Biology and Medicine 1999 University Press Oxford
25. T.M. Hyde, D.R. Weinberger, J.E. Kleinman, M.F. Egan, L.L. Wing, and R.J. Wyatt Persistent catalepsy associated with severe dyskinesias in rats treated with chronic injections of haloperidol decanoate Psychopharmacology 18 2 1995 142 149
26. A. Jager, V. Stefani, S.S. Guterres, and A.R. Pohlmann Physico-chemical characterization of nanocapsule polymeric wall using fluorescent benzazole probes Int. J. Pharm. 338 2007 297 305
27. D.S. Kerr, L.R. Bevilaqua, J.S. Bonini, J.I. Rossato, C.A. Kohler, J.H. Medina, I. Izquierdo, and M. Cammarota Angiotensin II blocks memory consolidation through an AT(2) receptor dependent mechanism Psychopharmacology 179 2005 529 535
28. J. Kreuter, D. Shamenkov, V. Petrov, P. Ramge, K. Cychutek, C. Koch-Brandt, and R. Alyautdin Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier J. Drug Target. 10 2002 317 325
29. J. Kreuter Application of nanoparticles for the delivery of drugs to the brain Int. Congr. Ser. 1277 2005 85 94
30. H.Y. Meltzer, P.A. Thompson, M.A. Lee, and R. Ranjan Neuropsychologic déficits in schizophrenia: relation to social function and effect of antipsychotic drug treatment Neuropsychopharmacology 14 1995 27S 33S
31. V. Mohanraj, and Y. Chen Nanoparticles-a review Trop. J. Pharm. Res. 5 2006 561 573
32. C.E. Mora-Huertas, H. Fessi, and A. Elaissari Polymer-based nanocapsules for drug delivery Int. J. Pharm. 385 2010 113 142
33. E. Mutschler, H. Derendorf, M. Schafer-Korting, K. Elrod, and K.S. Estes Drug actions: basic principles and therapeutic aspects 1995 Medpharm Scientitific Publishers Stuttgart pp. 116-125
34. M.S. Muthu, and S. Singh Studies on biodegradable polymeric nanoparticles of risperidone: in vitro and in vivo evaluation Nanomedicine 3 2008 305 319
35. M.S. Muthu, M.K. Rawat, A. Mishra, and S. Singh PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation Nanomedicine 5 2009 323 333
36. P.S. Naidu, A. Singh, and S.K. Kulkami Quercetin, a bioflavonoid attenuates haloperidol-induced orofacial dyskinesia Neuropharmacology 44 2003 1100 1106
37. R.C. Nagarwal, S. Kant, P.N. Singh, P. Maiti, and J.K. Pandit Polymeric nanoparticulate system: a potential approach for ocular drug delivery J. Controlled Release 136 2009 2 13
38. H. Ohkawa, N. Ohishi, and K. Yagi Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
39. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates sixth ed. 2007 Elsevier Amsterdam
40. T. Ponto, N.I. Ismail, A.B. Abdul Majeed, N.H. Marmaya, and Z.A. Zakaria A prospective study on the pattern of medication use for schizophrenia in the outpatient pharmacy department, Hospital Tengku Ampuan Rahimah, Selangor, Malaysia. Methods Find. Exp. Clin. Pharmacol. 32 2000 427 432
41. J.B.T. Rocha, J.E.T. Santos, L.K. Rocha, and E.R. Kleinpaul Undernutrition during suckling changes the sensitivity to haloperidol and chlorpromazine in two behavioural measures in weaning rats Pharmacol. Toxicol. 80 1997 114 123
42. R.E. See Striatal dopamine metabolism increases during long-term haloperidol administration in rats but shows tolerance in response to acute challenge with raclopride Neurosci. Lett. 129 1991 265 268
43. D. Taylor Psychopharmacology and adverse effects of antipsychotic long-acting injections: a review Br. J. Psychiatry 195 5 2009 S13 S19
44. A.M. Teixeira, L.G. Müller, P. Reckziegel, N. Boufleur, C.S. Pase, J.G. Villarinho, R. Fachinetto, J. Ferreira, and J.B.T. Rocha Bürger ME. Beneficial effects of an innovative exercise model on motor and oxidative disorders induced by haloperidol in rats Neuropharmacology 60 2011 432 438
45. F. Trevizol, D.M. Benvegnú, R.C.S. Barcelos, C.S. Pase, H. Segat, V.T. Dias, G.S. Dolci, N. Boufleur, P. Reckziegel, and M.E. Bürger Comparative study between two animal models of extrapyramidal movement disorders: prevention and reversion by pecan nut shell aqueous extract Behav. Brain Res. 221 2011 13 18
46. G. Tsai, D.C. Goff, R.W. Change, J. Flood, L. Bair, and J.T. Coyle Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia Am. J. Psychiatry 155 1998 1207 1213
47. C.X. Wang, L.S. Huang, L.B. Hou, L. Jiang, Z.T. Yan, Y.L. Wang, and Z.L. Che Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model Brain Res. 1261 2009 91 99
48. T.W. Wu, F.L. Yen, L.T. Lin, T.R. Tsai, C.C. Lin, and T.M. Cham Preparation, physicochemical characterization, and antioxidant effects of quercetin nanoparticles Int. J. Pharm. 346 2008 160 168
49. T. Xin-Hua, L. Xiao-Ning, W. Feng, Z. Huang, P. Wang, L. Ren, and Y. Diao Enhanced brain targeting of temozolomide in polysorbate-80 coated polybutylcyanoacrylate nanoparticles Int. J. Nanomed. 6 2011 445 452
50. Y. Zhang, H. Xu, J. He, B. Yan, W. Jiang, X. Li, and X.M. Li Quetiapine reverses altered locomotor activity and tyrosine hydroxylase immunoreactivity in rat caudate putamen following long-term haloperidol treatment Neurosci. Lett. 420 2007 66 71
51. L. Zhu, J. Ma, N. Jia, Y. Zhao, and H. Shen Chitosan-coated magnetic nanoparticles as carriers of 5-Fluorouracil: preparation, characterization and cytotoxicity studies Colloids Surf. B: Biointerfaces 68 2009 1 6